Key result
Weight loss of ≥5% in women with metabolically healthy obesity significantly increased adiponectin levels by 4.55 μg/ml and decreased pro-inflammatory adipocytokines and HOMA index.
Why the study?
Does weight loss of ≥ 5% improve adipocytokine levels and cardiometabolic risk factors in women with metabolically healthy obesity?
Population
77 female patients aged 19-59 years with obesity, including 44 with metabolically healthy obesity and 33…
Comparison
Weight loss of ≥ 5% at 6 months achieved via… vs Metabolically unhealthy obesity patients…
Design
Cohort
Follow-up
6 months
Authors
Loading...
Weight loss in metabolically healthy obesity improves the proinflammatory adipocytokine profile and insulin resistance, indicating the need for obesity treatment regardless of metabolic phenotype.
Cohort (n=77)
Open-label
No
Does weight loss of ≥ 5% improve adipocytokine levels and cardiometabolic risk factors in women with metabolically healthy obesity?
Absolute Event Rate: 4.55% vs 1.97%
p-value: p=<0.05
Weight loss in metabolically healthy obesity improves the proinflammatory adipocytokine profile and insulin resistance, indicating the need for obesity treatment regardless of metabolic phenotype.
Романцова et al. (2018) conducted a cohort in Metabolically healthy obesity (n=77). Weight loss ≥ 5% vs. Metabolically unhealthy obesity (MUHO) was evaluated on Change in adiponectin level (μg/ml) (p=<0.05). Weight loss of ≥5% in women with metabolically healthy obesity significantly increased adiponectin levels by 4.55 μg/ml and decreased pro-inflammatory adipocytokines and HOMA index.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: